Bucketing iComponent as a 'display parts stock' gets the thesis wrong from the start. In 1Q26, revenue was ₩9.74B, with COATED PET (barrier coating film) at ₩8.06B — 82.8% of total. The company's identity has already changed. FY2025 revenue of ₩34.65B (YoY -6.6%) produced operating profit of ₩6.04B (+132.6%) and OPM of 17.4% — a clear mix-improvement signal where profits surged despite falling sales. 1Q26 repeated the same structure: revenue ₩9.74B, OP ₩1.66B, OPM 17.0%. Market cap ~₩42.1B, TTM PER ~6.0x. On raw numbers alone, this is obvious undervaluation. However, four unverified variables remain: no formal sell-side report within 90 days, undisclosed revenue breakdown by customer and product, inability to isolate FX effects, and the June 29 EGM treasury share disposal plan. The core question is whether 'COATED PET at 80% mix + OPM in the 17% range repeats in 2Q26.'
Fundamentally, Pamicell is already an electronic materials company. In 1Q26, low-dielectric electronic materials revenue reached ₩26.0 billion, 71% of total revenue, with OPM in the mid-30% range. KRX also changed its industry classification from basic pharmaceutical substance manufacturing to electronic component manufacturing as of 2026-05-04. But the two-week flow data from 5/4 to 5/18 says the market has not yet reclassified it. Daeduck Electronics rose +22.7% with foreign + institutional net buying of ₩64.8 billion, while Pamicell fell -17.9% with only ₩1.6 billion of combined buying. Its price correlation is closer to Doosan and ST Pharm than Daeduck. The business has changed into electronic materials, but the stock is still trapped in biotech inertia.
The two-week flow picture for Pearl Abyss does not yet qualify as a supply-demand turn. From May 4 to May 18, the stock fell 21.7% from ₩58,500 to ₩45,800, with foreigners and institutions net selling approximately ₩30.1B and ₩26.4B respectively. That said, after the May 13 forced-selling episode, foreigners and program trading posted partial recoveries, and short-selling share fell from its peak. The core battle is between foreign bargain re-entry and continued selling by institutions, private funds, and securities firms. This is a flow-bottom test, not a flow turn. A genuine reversal requires holding ₩45,500–₩46,000, reclaiming ₩47,200, and seeing durable buying from trust funds, pension funds, and insurers.
Huawei's CloudMatrix 384 does not mean China beat NVIDIA on efficiency. It is a structure that bypasses the GB200 NVL72 in aggregate by lashing together 384 Ascend chips, drawing 559kW of power, and connecting them with massive optical links. The real alpha is not in direct Huawei suppliers but in the inspection, metrology, and high-difficulty consumables demand created when China is forced to scale up its own fab, equipment, and consumables investment. 티씨케이, 넥스틴, and 코미코 are not the same China theme. 티씨케이 is a confirmed consumables recovery play with 1Q26 China normalization in the numbers. 넥스틴 is a bet on 2H26 China PO resumption. 코미코 is global foundry quality with a China option attached.
The May 14-15 Trump-Xi summit in Beijing produced a managed truce, not a grand bargain. The more important signal came outside the room: the U.S. cleared H200 sales to China, but no chips have shipped because China has not allowed purchases to proceed. At the same time, Huawei's CloudMatrix 384 shows how China can offset weaker chips with more chips, more power, and more optical interconnects. ITIF estimates that in a full semiconductor decoupling scenario, U.S. firms could lose USD 77B of China-related sales in the first year, while South Korean firms could gain USD 21B. For Korea, the short term is favorable for memory and AI components; the long term brings standard fragmentation and dual-supply-chain costs.
Pearl Abyss's 1Q26 results proved Crimson Desert's commercial success and margin power. Meritz estimates 3.089M recognized Crimson Desert copies in 1Q, implying an accounting ASP of about KRW 86,300 per copy on KRW 266.5B in Crimson Desert revenue. Applying the same ASP to company 2Q Crimson Desert guidance of KRW 224.2B-276.5B implies 2.6M-3.2M recognized copies, with a midpoint near 2.9M. A 3M-recognized-copy 2Q is therefore a reasonable base case. But the market debate has already moved from a 2Q cliff to a 2027 earnings cliff. The next re-rating depends on whether DLC, Asia/China expansion, platform extension, capital return, or DokeV visibility can lift 2027 operating profit from the KRW 200B range toward KRW 300B+.